Post by Moderna on X
Moderna@moderna_tx
XToday we announced that the European Commission (EC) has granted marketing authorization for mCOMBRIAX® (mRNA-1083), our mRNA combination vaccine for active immunization for the prevention of influenza disease and COVID-19 caused by SARS-CoV-2 in individuals 50 years of age and

188 likes0 repliesPosted Apr 21, 2026